PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting PCSK9 and reducing the degradation of LDL receptors; thus, they are impacting the management of dyslipidemia to the pre...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1138787/full |
| _version_ | 1827955949629865984 |
|---|---|
| author | Hongzhen Chen Xiaomin Chen |
| author_facet | Hongzhen Chen Xiaomin Chen |
| author_sort | Hongzhen Chen |
| collection | DOAJ |
| description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting PCSK9 and reducing the degradation of LDL receptors; thus, they are impacting the management of dyslipidemia to the prevention of cardiovascular events. Recent guidelines recommend PCSK9 inhibitors for patients who fail to achieve target lipids after ezetimibe/statin therapy. As PCSK9 inhibitors have been demonstrated to significantly and safely reduce LDL-C, discussions have begun to explore its optimal timing in coronary artery disease, especially in subjects with acute coronary syndrome (ACS). Also, their additional benefits, such as anti-inflammatory effects, plaque regression effects, and cardiovascular event prevention, have become the focus of recent research. Several studies, including EPIC-STEMI, suggest the lipid-lowering effects of early PCSK9 inhibitors in ACS patients, while some studies such as PACMAN-AMI suggest that early PCSK9 inhibitors can decelerate plaque progression and reduce short-term risks of cardiovascular events. Thus, PCSK9 inhibitors are entering the era of early implementation. In this review, we are committed to summarizing the multidimensional benefits of early implementation of PCSK9 inhibitors in ACS. |
| first_indexed | 2024-04-09T14:55:58Z |
| format | Article |
| id | doaj.art-01cf17aebf3546f0b24118894851486b |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-09T14:55:58Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-01cf17aebf3546f0b24118894851486b2023-05-02T04:46:20ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-05-011010.3389/fcvm.2023.11387871138787PCSK9 inhibitors for acute coronary syndrome: the era of early implementationHongzhen ChenXiaomin ChenProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting PCSK9 and reducing the degradation of LDL receptors; thus, they are impacting the management of dyslipidemia to the prevention of cardiovascular events. Recent guidelines recommend PCSK9 inhibitors for patients who fail to achieve target lipids after ezetimibe/statin therapy. As PCSK9 inhibitors have been demonstrated to significantly and safely reduce LDL-C, discussions have begun to explore its optimal timing in coronary artery disease, especially in subjects with acute coronary syndrome (ACS). Also, their additional benefits, such as anti-inflammatory effects, plaque regression effects, and cardiovascular event prevention, have become the focus of recent research. Several studies, including EPIC-STEMI, suggest the lipid-lowering effects of early PCSK9 inhibitors in ACS patients, while some studies such as PACMAN-AMI suggest that early PCSK9 inhibitors can decelerate plaque progression and reduce short-term risks of cardiovascular events. Thus, PCSK9 inhibitors are entering the era of early implementation. In this review, we are committed to summarizing the multidimensional benefits of early implementation of PCSK9 inhibitors in ACS.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1138787/fullPCSK9 inhibitorsacute coronary syndromecoronary heart diseaseearly implementationlow-density lipoprotein cholesterol |
| spellingShingle | Hongzhen Chen Xiaomin Chen PCSK9 inhibitors for acute coronary syndrome: the era of early implementation Frontiers in Cardiovascular Medicine PCSK9 inhibitors acute coronary syndrome coronary heart disease early implementation low-density lipoprotein cholesterol |
| title | PCSK9 inhibitors for acute coronary syndrome: the era of early implementation |
| title_full | PCSK9 inhibitors for acute coronary syndrome: the era of early implementation |
| title_fullStr | PCSK9 inhibitors for acute coronary syndrome: the era of early implementation |
| title_full_unstemmed | PCSK9 inhibitors for acute coronary syndrome: the era of early implementation |
| title_short | PCSK9 inhibitors for acute coronary syndrome: the era of early implementation |
| title_sort | pcsk9 inhibitors for acute coronary syndrome the era of early implementation |
| topic | PCSK9 inhibitors acute coronary syndrome coronary heart disease early implementation low-density lipoprotein cholesterol |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1138787/full |
| work_keys_str_mv | AT hongzhenchen pcsk9inhibitorsforacutecoronarysyndrometheeraofearlyimplementation AT xiaominchen pcsk9inhibitorsforacutecoronarysyndrometheeraofearlyimplementation |